Prevention of Preterm Birth in Pregnant Women at Risk Identified by Ultrasound: Evaluation of Two Treatment Strategies (PESAPRO)
Primary Purpose
Early Onset of Delivery Before 37 Weeks
Status
Completed
Phase
Phase 4
Locations
Spain
Study Type
Interventional
Intervention
Vaginal micronized progesterone
Cervical pessary
Sponsored by

About this trial
This is an interventional prevention trial for Early Onset of Delivery Before 37 Weeks
Eligibility Criteria
Inclusion Criteria:
- Pregnant women with short cervix (=< 25 mm) identified by use of routine transvaginal ultrasonography at 19-22 weeks of gestation.
- Single pregnancy
- Women older than 18 year-old
- Women sign informed consent according GCP and local legislation
- Gestational age at randomization between 20+1 and 23+6 weeks.
Exclusion Criteria:
- Major fetal abnormalities
- Major uterine abnormalities
- Placenta praevia during current pregnancy
- Vaginal bleeding or ruptured membranes in the moment of randomization
- Cervical cerclage in situ
- History of cone biopsy
- Allergic to peanuts
- Contraindication for Progesterone usage.
- Active treatment with Progesterone at randomization.
- History of 3 or more premature labor.
- If in the investigator's opinion, there are findings on physical examination, abnormalities in the results of clinical analyzes or other medical factors, social or psycho-social that could negatively influence.
- Women unable to give the informed consent
Sites / Locations
- University Hospital San Juan de Alicante
- Igualada Hospital
- University Hospital Príncipe de Asturias
- University Hospital Fundación de Alcorcón
- University Hospital Madrid Monte Principe
- University Hospital Fuenlabrada
- University Hospital de Getafe
- University Hospital Severo Ochoa
- University Hospital Puerta de Hierro
- University Hospital Rey Juan Carlos I
- University Hospital Mostoles
- Hospital Infanta Sofía
- Hospital Infanta Elena
- Palamos Hospital
- Hospital Universitario de Donostia
- University Hospital Quiron Dexeus
- Burgos University Hospital
- Ciudad Real General University Hospital
- Guadalajara General University Hospital
- University Hospital de León
- Sanitas La Zarzuela Hospital
- University Hospital Ramón y Cajal
- Sanitas La Moraleja Hospital
- University Hospital Quirón Málaga
- Valladolid Clinic Universitary Hospital
- University Hospital Rio Hortega
- University Hospital Miguel Servet
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Vaginal micronized progesterone
Cervical pessary
Arm Description
200 mg vaginal route per day
Cervical pessary certified by European Conformity (CE0482, MED/CERT ISO 9003/EN 46003;Dr Arabin, lower larger diameter 70 mm, height 30 mm,and upper smaller diameter 32 mm)
Outcomes
Primary Outcome Measures
Proportion of spontaneous preterm birth before 34 weeks of gestation
Secondary Outcome Measures
Proportion of spontaneous preterm birth before 37 weeks of gestation
Proportion of Spontaneous preterm birth before 28 weeks of gestation
Rate of premature rupture of membranes before 34 weeks of gestation
Weight at birth
Rate of fetal and neonatal mortality
Symptomatic vaginal infections during treatment period
Proportion of participants with adverse events
Rate of Chorioamnionitis during third term
Need of admission because of premature labor before 34 weeks of gestation
Rate of neonatal morbidity
Full Information
NCT ID
NCT01643980
First Posted
June 12, 2012
Last Updated
October 14, 2016
Sponsor
Dra.Cristina Martinez Payo
1. Study Identification
Unique Protocol Identification Number
NCT01643980
Brief Title
Prevention of Preterm Birth in Pregnant Women at Risk Identified by Ultrasound: Evaluation of Two Treatment Strategies
Acronym
PESAPRO
Official Title
Prevention of Preterm Birth in Pregnant Women at Risk Identified by Ultrasound: Evaluation of Two Treatment Strategies
Study Type
Interventional
2. Study Status
Record Verification Date
October 2016
Overall Recruitment Status
Completed
Study Start Date
August 2012 (undefined)
Primary Completion Date
March 2016 (Actual)
Study Completion Date
April 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Dra.Cristina Martinez Payo
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The preterm birth is considered as a main problem in the modern obstetrics, being the responsible of greatest of 50% neonatal morbimortality and heavy costs. Despite the significant medical advances, the rate of prematurity has not declined over the past 40 years and even continues to rise in the developed countries. In order to decrease the prematurity is necessary that two premises: to identify the pregnant women at risk of preterm birth, and dispose of useful measures aimed at prolonging the pregnancy and therefore avoid preterm delivery. The investigators propose a clinical trial with the objective to identify effective strategies to reduce the premature birth (34 weeks and earlier) rate in the population of pregnant women at risk for premature birth, which will be identified by ultrasound during the second trimester of their pregnancy.
The investigators intend to compare two accepted strategies: administration of progesterone (vaginally) or the placement of vaginal pessaries. These 2 strategies are affordable, easy to apply, and they present very few maternal-fetal secondary effects.
Detailed Description
The preterm birth is considered as a main problem in the modern obstetrics, being the responsible of greatest of 50% neonatal morbimortality and heavy costs. Despite the significant medical advances, the rate of prematurity has not declined over the past 40 years and even continues to rise in the developed countries. In order to decrease the prematurity is necessary that two premises: to identify the pregnant women at risk of preterm birth, and dispose of useful measures aimed at prolonging the pregnancy and therefore avoid preterm delivery. Since 1990, many published articles describe the sonographic measurement of the cervix from the week 16 as method of population screening to detect women at risk. Several studies provide evidence about an inverse relationship between the cervical length and the risk of preterm delivery. For this reason, if there is an effective intervention for patients with cervix short (about < 25mm), made this measure in the middle of the second term, the investigators could reduce the prematurity. Regarding possible therapeutic strategies, recent published data demonstrate the effective of vaginal progesterone and cervical pessary in this population. However, both treatments have never been compared and none of the two strategies are indicated in this population. Therefore it results necessary to compare both treatments in order to establish clinical recommendations. The investigators propose a clinical trial to compare two accepted strategies: administration of progesterone (vaginally) or the placement of vaginal pessaries in order to reduce the premature birth (34 weeks and earlier) rate in the population of pregnant women at risk for premature birth, which will be identified by ultrasound during the second trimester of their pregnancy.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Early Onset of Delivery Before 37 Weeks
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
254 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Vaginal micronized progesterone
Arm Type
Experimental
Arm Description
200 mg vaginal route per day
Arm Title
Cervical pessary
Arm Type
Active Comparator
Arm Description
Cervical pessary certified by European Conformity (CE0482, MED/CERT ISO 9003/EN 46003;Dr Arabin, lower larger diameter 70 mm, height 30 mm,and upper smaller diameter 32 mm)
Intervention Type
Drug
Intervention Name(s)
Vaginal micronized progesterone
Intervention Description
200 mg vaginal route per day
Intervention Type
Device
Intervention Name(s)
Cervical pessary
Intervention Description
Cervical pessary certified by European Conformity (CE0482, MED/CERT ISO 9003/EN 46003;Dr Arabin, lower larger diameter 70 mm, height 30 mm,and upper smaller diameter 32 mm)
Primary Outcome Measure Information:
Title
Proportion of spontaneous preterm birth before 34 weeks of gestation
Time Frame
up to 11 weeks (from date of randomization until delivery)
Secondary Outcome Measure Information:
Title
Proportion of spontaneous preterm birth before 37 weeks of gestation
Time Frame
up to 17 weeks (from date of randomization until delivery)
Title
Proportion of Spontaneous preterm birth before 28 weeks of gestation
Time Frame
up to 8 weeks (from date of randomization until delivery)
Title
Rate of premature rupture of membranes before 34 weeks of gestation
Time Frame
up to 11 weeks (from date of randomization until delivery)
Title
Weight at birth
Time Frame
up to 21 weeks (from date of randomization until delivery)
Title
Rate of fetal and neonatal mortality
Time Frame
From date of randomization until the date of delivery, assessed up 21 weeks
Title
Symptomatic vaginal infections during treatment period
Time Frame
From date of randomization until the date of delivery, assessed up 21 weeks
Title
Proportion of participants with adverse events
Time Frame
From date of randomization until the date of delivery, assessed up 21 weeks
Title
Rate of Chorioamnionitis during third term
Time Frame
From date of randomization until the date of delivery, assessed up 21 weeks
Title
Need of admission because of premature labor before 34 weeks of gestation
Time Frame
up to 14 weeks (from date of randomization until delivery)
Title
Rate of neonatal morbidity
Time Frame
From date of randomization until the date of delivery, assessed up 21 weeks
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Pregnant women with short cervix (=< 25 mm) identified by use of routine transvaginal ultrasonography at 19-22 weeks of gestation.
Single pregnancy
Women older than 18 year-old
Women sign informed consent according GCP and local legislation
Gestational age at randomization between 20+1 and 23+6 weeks.
Exclusion Criteria:
Major fetal abnormalities
Major uterine abnormalities
Placenta praevia during current pregnancy
Vaginal bleeding or ruptured membranes in the moment of randomization
Cervical cerclage in situ
History of cone biopsy
Allergic to peanuts
Contraindication for Progesterone usage.
Active treatment with Progesterone at randomization.
History of 3 or more premature labor.
If in the investigator's opinion, there are findings on physical examination, abnormalities in the results of clinical analyzes or other medical factors, social or psycho-social that could negatively influence.
Women unable to give the informed consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sara Cruz Melguizo, Dr
Organizational Affiliation
University Hospital Puerta de Hierro Majadahonda
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Cristina Martinez Payo, Dr.
Organizational Affiliation
University Hospital Puerta de Hierro Majadahonda
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospital San Juan de Alicante
City
Sant Joan d'Alacant
State/Province
Alicante
ZIP/Postal Code
03550
Country
Spain
Facility Name
Igualada Hospital
City
Igualada
State/Province
Barcelona
ZIP/Postal Code
08700
Country
Spain
Facility Name
University Hospital Príncipe de Asturias
City
Alcalá de Henarés
State/Province
Madrid
ZIP/Postal Code
28805
Country
Spain
Facility Name
University Hospital Fundación de Alcorcón
City
Alcorcón
State/Province
Madrid
ZIP/Postal Code
28922
Country
Spain
Facility Name
University Hospital Madrid Monte Principe
City
Boadilla del Monte
State/Province
Madrid
ZIP/Postal Code
28660
Country
Spain
Facility Name
University Hospital Fuenlabrada
City
Fuenlabrada
State/Province
Madrid
ZIP/Postal Code
28942
Country
Spain
Facility Name
University Hospital de Getafe
City
Getafe
State/Province
Madrid
ZIP/Postal Code
28905
Country
Spain
Facility Name
University Hospital Severo Ochoa
City
Leganés
State/Province
Madrid
ZIP/Postal Code
28911
Country
Spain
Facility Name
University Hospital Puerta de Hierro
City
Majadahonda
State/Province
Madrid
ZIP/Postal Code
28222
Country
Spain
Facility Name
University Hospital Rey Juan Carlos I
City
Mostoles
State/Province
Madrid
ZIP/Postal Code
28933
Country
Spain
Facility Name
University Hospital Mostoles
City
Móstoles
State/Province
Madrid
ZIP/Postal Code
28935
Country
Spain
Facility Name
Hospital Infanta Sofía
City
San Sebastián de los Reyes
State/Province
Madrid
ZIP/Postal Code
28702
Country
Spain
Facility Name
Hospital Infanta Elena
City
Valdemoro
State/Province
Madrid
ZIP/Postal Code
28040
Country
Spain
Facility Name
Palamos Hospital
City
Gerona
State/Province
Palamos
ZIP/Postal Code
17320
Country
Spain
Facility Name
Hospital Universitario de Donostia
City
Donostia
State/Province
San Sebastian
ZIP/Postal Code
20080
Country
Spain
Facility Name
University Hospital Quiron Dexeus
City
Barcelona
ZIP/Postal Code
08028
Country
Spain
Facility Name
Burgos University Hospital
City
Burgos
ZIP/Postal Code
09006
Country
Spain
Facility Name
Ciudad Real General University Hospital
City
Ciudad Real
ZIP/Postal Code
13005
Country
Spain
Facility Name
Guadalajara General University Hospital
City
Guadalajara
ZIP/Postal Code
19002
Country
Spain
Facility Name
University Hospital de León
City
León
ZIP/Postal Code
24071
Country
Spain
Facility Name
Sanitas La Zarzuela Hospital
City
Madrid
ZIP/Postal Code
28023
Country
Spain
Facility Name
University Hospital Ramón y Cajal
City
Madrid
ZIP/Postal Code
28046
Country
Spain
Facility Name
Sanitas La Moraleja Hospital
City
Madrid
ZIP/Postal Code
28050
Country
Spain
Facility Name
University Hospital Quirón Málaga
City
Málaga
ZIP/Postal Code
29004
Country
Spain
Facility Name
Valladolid Clinic Universitary Hospital
City
Valladolid
ZIP/Postal Code
47005
Country
Spain
Facility Name
University Hospital Rio Hortega
City
Valladolid
ZIP/Postal Code
47012
Country
Spain
Facility Name
University Hospital Miguel Servet
City
Zaragoza
ZIP/Postal Code
50009
Country
Spain
12. IPD Sharing Statement
Citations:
PubMed Identifier
30204689
Citation
Cruz-Melguizo S, San-Frutos L, Martinez-Payo C, Ruiz-Antoran B, Adiego-Burgos B, Campillos-Maza JM, Garcia-Gonzalez C, Martinez-Guisasola J, Perez-Carbajo E, Teulon-Gonzalez M, Avendano-Sola C, Perez-Medina T. Cervical Pessary Compared With Vaginal Progesterone for Preventing Early Preterm Birth: A Randomized Controlled Trial. Obstet Gynecol. 2018 Oct;132(4):907-915. doi: 10.1097/AOG.0000000000002884. Erratum In: Obstet Gynecol. 2018 Dec;132(6):1507.
Results Reference
derived
PubMed Identifier
26407852
Citation
Cabrera-Garcia L, Cruz-Melguizo S, Ruiz-Antoran B, Torres F, Velasco A, Martinez-Payo C, Avendano-Sola C; PESAPRO trial Group. Evaluation of two treatment strategies for the prevention of preterm birth in women identified as at risk by ultrasound (PESAPRO Trial): study protocol for a randomized controlled trial. Trials. 2015 Sep 25;16:427. doi: 10.1186/s13063-015-0964-y.
Results Reference
derived
Learn more about this trial
Prevention of Preterm Birth in Pregnant Women at Risk Identified by Ultrasound: Evaluation of Two Treatment Strategies
We'll reach out to this number within 24 hrs